Tivic Health Systems, Inc.: Business Overview, Financials & Competitive Analysis
Tivic Health Systems, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Speculative biotech play dependent on government approval and manufacturing scale-up with minimal financial runway. With a market cap of only $2.16M and stock trading at $0.84, the company faces severe liquidity and market confidence challenges. While the BARDA engagement represents a significant validation opportunity for Entolimod, extreme financial.
What is Tivic Health Systems, Inc.'s industry? Tivic Health Systems, Inc. (tivichealth.com) operates in Immunotherapeutics / Bioelectronic Medicine / Contract Manufacturing. AskCyborg classifies Tivic Health Systems, Inc. under Immunotherapeutics / Bioelectronic Medicine / Contract Manufacturing in its company registry.
Tivic Health Systems is a diversified therapeutics company that harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. The company's lead drug candidate, Entolimod™ to tre...
Cyborg Score thesis
Speculative biotech play dependent on government approval and manufacturing scale-up with minimal financial...
Read the full analyst-debate transcript →Get the Latest Tivic Health Systems, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTivic Health Systems, Inc. Overview
Pro stress-test →Tivic Health Systems is a diversified therapeutics company that harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. The company's lead drug candidate, Entolimod™ to treat Acute Radiation Syndrome (ARS), is in late-stage development.
Strategic Profile
Pro stress-test →Tivic has evolved into a diversified immunotherapeutics and health technology company. In January 2026, the company presented Entolimod at a BARDA TechWatch meeting with U.S. defense and health agencies, showcasing clinical results and manufacturing readiness, with BARDA requesting expedited follow-up to discuss potential inclusion in the Strategic National Stockpile.
Competitive Landscape
Pro stress-test →Entolimod is a TLR5 agonist in late-stage development for Acute Radiation Syndrome, competing in the niche radiation countermeasure market. Key competitors include established biotech firms and government-funded radiation response programs. The company's legacy ClearUP consumer product operates in the OTC sinus relief market against traditional and electrical devices.
Industry Context
Tivic Health Systems, Inc. operates in Immunotherapeutics / Bioelectronic Medicine / Contract Manufacturing.
Key facts
Founded: 2016 · Headquarters: Fremont, CA · Market cap: $2.16M